Education
About Us
Working with TipRanks
Follow Us
Terumo (JP:4543)
:4543
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2026 (Q1)Consensus EPS Forecast
24.45Last Year’s EPS
22.82Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -2.28%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with record-breaking revenue and profit growth, driven by strategic business expansions and regional success. However, significant one-time expenses and potential tariff impacts pose challenges. The outlook for future growth remains positive, with expectations of continued revenue and profit increases.Company Guidance
During Terumo's Financial Results Presentation for the fourth quarter of fiscal year 2025, CFO Jin Hagimoto provided guidance for the upcoming year. Terumo expects revenue growth of 7% on a local currency basis, driven by company-wide expansion, particularly in Blood and Cell Technologies. Operating profit is anticipated to increase by 32%, significantly outpacing sales growth due to the absence of previous year's one-time expenses and continued profit improvement measures. The company aims to improve its operating margin by 3.3 percentage points to 18.5%. Terumo is also navigating potential impacts from U.S. reciprocal tariffs, which could affect profitability, but plans to mitigate these through strategic pricing adjustments. The company continues to invest in growth, with a focus on expanding its CDMO business and increasing production capacity, as evidenced by its recent acquisition of a WuXi Biologics factory in Germany.Record-Breaking Revenue
Sales revenue surpassed JPY 1 trillion for the first time with a 12% increase over the previous year, driven by global demand growth and a weaker yen.
Profit Growth
Operating profit reached a record high for the fourth consecutive year and net income and free cash flow also hit record highs.
Future Growth Expectations
For fiscal 2025, revenue is expected to grow by 7% on a local currency basis, and operating profit is projected to increase by 32%.
Regional Success
All regions, especially the Americas and Europe, showed double-digit growth in local currency terms.
Cardiovascular and Blood Solutions Growth
Significant contributions to revenue growth came from the cardiovascular and Blood and Cell Technologies segments.
CDMO Business Expansion
Terumo's CDMO business is expanding globally with the acquisition of a European base, enhancing its competitive edge in the CDMO market.
JP:4543 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JP:4543 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | ¥2784.50 | ¥2726.50 | -2.08% |
Feb 13, 2025 | ¥2779.69 | ¥2827.47 | +1.72% |
Nov 07, 2024 | ¥2956.87 | ¥2965.83 | +0.30% |
Aug 08, 2024 | ¥2463.69 | ¥2462.21 | -0.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Terumo (JP:4543) report earnings?
Terumo (JP:4543) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Terumo (JP:4543) earnings time?
Terumo (JP:4543) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Terumo stock?
The P/E ratio of Terumo is N/A.
What is JP:4543 EPS forecast?
JP:4543 EPS forecast for the fiscal quarter 2026 (Q1) is 24.45.